Late one night, Rylee Jebara woke to see dark objects lingering around his room.
"I was like, 'That's it, I'm seeing ghosts, I'm going to die,'" the aspiring artist said.
As those dark objects slowly came into focus, the 17-year-old realised they were just shadows of the doorframe and the furniture in his bedroom.
Then it dawned on him; he was able to see at night.
"I was absolutely terrified because I hadn't been able to see at night before, even as a child, with my vision impairment," he said.
Months earlierRyleebecame the first Australian to receive a groundbreaking eye therapy that helps treat an inherited retinal disease that leads to blindness.
The second Australian to receive the therapy was his younger brother, 15-year-old Saman.
ABC News: Brendan Esposito
Saman's vision loss hadn't progressed as far as Rylee's but was still significant.
"I wasn't completely blind.I could see at the daytime but not at night-time.At night-time, it's pitch black," Saman said.
Both siblingswere babies when they were diagnosed with leber congenital amaurosis, a severe form of retinal dystrophy.
It meanttheyboth had low vision, especially in dim light.
Their overall vision becameprogressively narrow, blurred and colours would fade until, eventually, they would lose their sight.
By the time Rylee was in year 6, he walked with the assistance of a cane. By high school, his deteriorating vision meant he had to learn new skills to navigate, includingasking people forhelp.
ABC News: Brendan Esposito
He said the stress meant he started to withdraw socially, as he became anxious about losing one of his senses.
As his vision deteriorated, so too did his grades, and he decided to drop out of school at the start of year 11.
Last year, his ophthalmologist suggested a new gene therapy designed specifically for people with his extremely rare eye condition.
After several rounds of tests, a group of experts agreed he met the criteria.
The therapycalled voretigene neparvovec, sold under the name LUXTURNA, was injected into the back of one of his eyes.
It's designed to treat mutations in the RPE65 gene, which is essential for good vision. It works by using a neutralised virus to carry a functional gene into the affected eye tissue. That enables the body to produce any proteins missing due to genetic mutation.
A month later, the surgery was repeated on Rylee'sother eye.The therapy then started working to repair his damaged gene.
This medication is the world's first gene therapy to treat a blinding eye condition, and one of the first gene replacements for any human disease.
It was approved for use in Australia last year and has only been used a handful of times around the world.
The treatment, which is free in Australia,doesn't work on everyone who has the condition, even if a patient is eligible for it.
Rylee and Saman's eligibility was assessed by a team from Ocular Gene and Cell Therapies Australia.
It isa collaboration between researchers and clinicians from the Genetic Eye Clinic at Sydney Children's Hospitals Network (SCHN), the Eye Genetics Research Unit and Stem Cell Medicine Group at the Children's Medical Research Institute (CMRI), the Save Sight Institute at Sydney Eye Hospital, and the University of Sydney.
"One of the really revolutionary things in relation to inherited retinal diseases is that we're now able to actually make a genetic diagnosis," Robyn Jamieson, head of the Eye Genetics Research Unit at SCHN and CMRI, said.
ABC News: Chris Taylor
Professor Jamieson said that wasn't the case 20 years ago when doctors struggled to even find a genetic diagnosis for patients like Rylee and Saman, let alone offer a therapy.
"We're now able to find those genetic answers," she said.
"By putting in this gene therapy, we can replace that faulty gene and it then works properly within the cells at the back of the eye to give the person a rescue of their vision and then also some improvements in their vision."
While neither Rylee nor Saman will ever have perfect vision, ProfessorJamieson saysthe benefits of the treatment are immeasurable.
"Patients like Rylee [can]read print when they hadn't been able tobefore," she said.
The use of gene therapy to treat genetic disorders dates back to the 1970s.In simple terms, it is when a person's defective genes are medically replaced by healthy ones.
And while gene therapy has had huge success, at other times it has yielded devastating outcomes, including the death of a patient in a clinical trial inthe 1990s.
Babies born with a rare, life-threatening genetic disorder that leaves them with little to no immunity have been cured with an experimental gene therapy.
Those setbacks have slowed the development of gene therapies, but many scientists and doctors arehopeful they can one day be used to treat a range of conditions.
Sydney haematologist and scientistJohn Raskois one.
"If you'd asked me 25 years ago whether gene therapy would be able to treat or cure blindness, I would have been very sceptical," saidProfessorRasko,the head ofcell and molecular therapies departmentat RPA Hospital in Sydney.
"But here we are now with a real treatment that's changing lives."
His department has been using gene therapy to try totreat conditions like haemophilia andthalassaemia, and cancers like leukaemia and lymphoma.
But ProfessorRasko said one of the challenges with gene therapy was inits delivery some bodies just don't accept it.
"We had to overcome the immune system because it often prevents viruseswhich we used to ferry the genes into getting to where they need to do their work," he said.
ForRylee and Saman, they are reaping the benefits.
Samansaid as his night vision had improved, sohad his self-confidence.
"It made me feel great [that] I can see stuff, so I don't have to trip on a bunch of stuff," Saman said.
"I'm able to walk at night and I'm able to go out with friends at night."
For Rylee, his improved vision has also allowed him to resume his creative art.
"Up until right before the procedure, I was in such a deep depression" he said.
"[I] couldn'tdraw on physical paper anymore and I couldn't do the things that I used to do.I was just hopeless in bed crying every day."
ABC News: Brendan Esposito
Now, he's planning on launching his own online store with another artist.
He is also makingtime to appreciate some of the things he never knew were possible.
"The other day I saw my first star in the sky," Rylee said.
"I was like, 'How can I see that tiny little sparkly thing in the sky?'
"Before I had the procedure, I just thought the sky was black and there was a Moon and there wereno stars or anything. I was like, 'People are trying to trick me into thinking there are sparkly things in the sky.'"
It's a similar story for Saman. Nowthe pair lovespending time sprawled out in thebackyard,staring up at the night sky.
"It looks beautiful," Saman said.
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 17th, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - BioSpace - October 17th, 2021
- Nic Chapman: my MS battle and the treatment that's given me hope - The Times - October 17th, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - October 13th, 2021
- Hematopoietic Stem Cells - October 13th, 2021
- 3D printing: Healthcare insiders' view on the tech - Verdict - October 13th, 2021
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - October 13th, 2021
- Mitochondrial superoxide dismutase overexpression and low oxygen conditioning hormesis improve the performance of irradiated sterile males |... - October 13th, 2021
- Researchers uncover how cancer cells use sugar residue to evade the immune system - News-Medical.net - October 13th, 2021
- The science and practicality of cultured meat The Stute - The Stute - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Le - Benzinga - October 11th, 2021
- Want To Support Healthy Bones? It's Time To Get Your Vitamin D In Check - mindbodygreen.com - October 11th, 2021
- Joint : Why Breast Cancer Awareness Matters, and How to Get It Done - marketscreener.com - October 11th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 7th, 2021
- Fasting boosts stem cells regenerative capacity | MIT ... - October 7th, 2021
- Adventist Review Online | Vaxed, Vexed, or Other? - Adventist Review - October 7th, 2021
- Sickle cell disease patients given hope for the future with first new treatment in 20 years - iNews - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WCAX - October 7th, 2021
- Is Stathmin-2 the Next Piece of the ALS Jigsaw Puzzle? - BioSpace - October 7th, 2021
- Ashley Black, Entrepreneur Of The Year For Health And Beauty, To Launch Best-Selling FasciaBlaster System - LatestLY - October 5th, 2021
- 25 Best Body Scrubs and Exfoliators in 2021 - the Trend Spotter - The Trend Spotter - October 5th, 2021
- Potential of exosomes as cell-free therapy | IJN - Dove Medical Press - October 2nd, 2021
- Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting - PRNewswire - October 2nd, 2021
- 12 of the best face serums 2021 - Medical News Today - October 2nd, 2021
- Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRA - Business Wire - October 2nd, 2021
- Envigo Announces Collaboration With Biocytogen to Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model - StreetInsider.com - September 29th, 2021
- Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows - Technology Networks - September 29th, 2021
- Sidney author warns against the abuses of technology Saanich News - Saanich News - September 27th, 2021
- Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated... - September 25th, 2021
- Dr. Sean Kelishadi provides stem cell therapy for facial procedures - Digital Journal - September 25th, 2021
- Pipeline of cell and gene therapies holds promise for repairing the Parkinsonian brain - EurekAlert - September 25th, 2021
- National Institutes of Health awards Children - EurekAlert - September 25th, 2021
- Amplitude Healthcare Acquisition : Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc (Form 8-K) -... - September 25th, 2021
- Can you mix and match COVID vaccines or boosters? What scientists and doctors say - CNET - September 22nd, 2021
- All The Reasons Why You Should Add Nutrient-Dense Mushrooms To Your Diet - NDTV Doctor - September 22nd, 2021
- My children know I have a terminal illness talking openly about cancer benefits all of us - iNews - September 22nd, 2021
- Orthopedic Regenerative Surgical Products Market Size to Expand Significantly by the End of 2031 - BioSpace - September 22nd, 2021
- Health tips from Dr. Oz and Dr. Roizen for 9-21-21 - The Commercial Dispatch - September 22nd, 2021
- Prescription Drugs Can Be Affordable and Innovative - Center For American Progress - September 18th, 2021
- The Promise of Regenerative Medicine to Treat Chronic Pain - Mega Doctor News - September 18th, 2021
- Precise CRISPR gene editing can correct the mutation that causes cystic fibrosis in mini-intestines - Massive Science - September 18th, 2021
- Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced ... - The Bakersfield Californian - September 18th, 2021
- A New Company With a Wild Mission: Bring Back the Woolly Mammoth - The New York Times - September 14th, 2021
- TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem... - September 14th, 2021
- Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer - pnas.org - September 14th, 2021
- What are the health benefits of nectarines? - Medical News Today - September 10th, 2021
- Time to humanize European health research with an action plan - POLITICO.eu - September 10th, 2021
- Tiny radio tags reveal the lives of Neotropical stingless bees - Massive Science - September 10th, 2021
- Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers... - September 8th, 2021
- Opdivo: Use with Yervoy, Side Effects, Cost, and More - Healthline - September 8th, 2021
- The Deal in Duluth: Catholics here on their own in seeking a religious exemption to being vaccinated - Duluth News Tribune - September 8th, 2021
- Diagnosis and Treatment of Three Primary Malignant Tumors | BCTT - Dove Medical Press - September 8th, 2021
- Jeff Bezos is reportedly funding Altos Labs, a new anti-ageing venture aiming to cheat death - Screen Shot - September 7th, 2021
- Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in... - September 2nd, 2021
- 11 of the best vitamin C serums 2021 - Medical News Today - September 2nd, 2021
- Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination - GOV.UK - September 2nd, 2021
- Japanese scientists have 3D printed a square of lab-grown wagyu beef - The A.V. Club - September 2nd, 2021
- This Company is Producing Bioprinted Fur, Wool & Eyelashes Which Could Make Fur Farms Obsolete - vegconomist - the vegan business magazine -... - September 2nd, 2021
- Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR- - Benzinga - September 1st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - September 1st, 2021
- KNUCKLES Role in Flower Clock; This Tiny Multi-Functional Protein Helps Complete Floral Development Properly at the Right Time - Science Times - September 1st, 2021
- Outlook on the Multiple Myeloma Drugs Global Market to 2026 - by Therapy, Drug Type, End-user, Distribution Channel and Region - Yahoo Finance - August 30th, 2021
- 6 Benefits of Not Eating Meat (or at Least Less of It) - Healthline - August 30th, 2021
- Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical... - August 25th, 2021
- The world's first 3D-printed Wagyu beef is revealed-it's marbling like the real thing - Texasnewstoday.com - August 25th, 2021
- Science-Backed Benefits of Prickly Pear Cactus - Healthline - August 25th, 2021
- AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics | More News | News Channels - PipelineReview.com - August 25th, 2021
- Educating California and the world on the benefits of hydrogen-powered transportation - H2 View - August 25th, 2021
- The Future is Fat: The Startups Looking to Fatten up Vegan Food - vegconomist - the vegan business magazine - August 25th, 2021
- This tech investor believes well soon live to 150. Here are his seven longevity hacks - The Irish Times - August 25th, 2021
- The Best New CBD Skincare Products Of 2021 (So Far) - Forbes - August 25th, 2021
- FDA Approval, Efficacy, Boosters and More: Which COVID Vaccine is Best for You? - NBC Chicago - August 25th, 2021
- Plant Stem Cell Market Technology Research and Global Outlook By Our Experts The Manomet Current - The Manomet Current - August 22nd, 2021
- AAPI's National Blood Donation Drive and Stem Cell Registry Launched, Honoring Fallen Covid Warriors The Indian Panorama - The Indian Panorama - August 22nd, 2021
- Stem Cells Facts and Quiz - WebMD - August 20th, 2021
- Stem cells | healthdirect - August 20th, 2021
- Research Study Published in Functional Foods Highlights Benefits of a Proprietary CBD Formula for Neurological Health - The Free Press Tampa - August 20th, 2021
- Leukemia Stem Cell Transplant: Benefits, Procedure, Side ... - August 20th, 2021
- Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC - GlobeNewswire - August 20th, 2021